July 11, 2022
Obsidian Therapeutics to Participate in a Panel at William Blair Biotech Focus Conference 2022
CAMBRIDGE, Mass., July 11, 2022 – Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that management will participate in the William Blair Biotech Focus Conference 2022. The event will be hosted in-person in New York City on July 12-13, 2022.
Paul Wotton, Ph.D., Chief Executive Officer of Obsidian, will be participating in the panel “Preparing for Launch: Navigating the Regulatory Landscape and Operationalizing Cell Therapies” on July 12, from 8:55 – 10:15 a.m. ET.
Obsidian will also take part in 1×1 investor meetings during the event.
OBX-115 is Obsidian’s lead cytoTIL15 program, currently in preclinical development for the treatment of patients with metastatic melanoma and other solid tumors. OBX-115 is a novel engineered tumor infiltrating lymphocyte (TIL) therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs, and to deliver enhanced persistence and improved anti-tumor activity. The Company expects to submit an IND for OBX-115 in mid-2022.
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.
Russo Partners, LLC